Citations

Clear

7552 citation(s) found for "Ku, Matthew".

Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma
Hobbs, Brian P. , Flowers, Christopher R. , Chihara, Dai , Maurer, Matthew J.

Mayo Clinic

Pharmacoepidemiology | August 6, 2024 | Volume: 3 | Issue: 3 | Pages: 252-264

10.3390/pharma3030017 Get It

The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in the field of lymphoma, as compared to traditional experimental clinical trials, are poised to significantly impact research methodologies, treatment strategies, and patient care. Current methods of clinical trials involve a well-controlled design and patient selection bias. Integrating RWE and RWD with experimental clinical trials offers a multifaceted approach to understanding lymphoma and enhancing patient outcomes. In this review, we discuss how RWE has helped shape lymphoma clinical trials, and we compare and evaluate evidence obtained from real-world lymphoma studies/databases with that obtained from clinical trials. We also discuss methods for utilizing surrogate endpoints to facilitate clinical trials and expedite drug development. RWE can be leveraged to bridge the gap between data obtained from clinical trial populations and the broader patient population encountered in clinical practice, by highlighting differences in outcomes and the need for effective treatment strategies across diverse patient groups.
Enhancing Health Literacy: Evaluating the Readability of Patient Handouts Revised by ChatGPT's Large Language Model
Swisher, Austin R. , Wu, Arthur W. , Liu, Gene C., Lee, Matthew , Carle, Taylor R., Tang, Dennis M. , Wu, Arthur W , Swisher, Austin R , Liu, Gene C.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | August 6, 2024 | Volume: 171 | Issue: 6 | Pages: 1751-1757

10.1002/ohn.927 | PMID 39105460 Get It

Abstract Objective To use an artificial intelligence (AI)‐powered large language model (LLM) to improve readability of patient handouts. Study Design Review of online material modified by AI. Setting Academic center. Methods Five handout materials obtained from the American Rhinologic Society (ARS) and the American Academy of Facial Plastic and Reconstructive Surgery websites were assessed using validated readability metrics. The handouts were inputted into OpenAI's ChatGPT‐4 after prompting: “Rewrite the following at a 6th‐grade reading level.” The understandability and actionability of both native and LLM‐revised versions were evaluated using the Patient Education Materials Assessment Tool (PEMAT). Results were compared using Wilcoxon rank‐sum tests. Results The mean readability scores of the standard (ARS, American Academy of Facial Plastic and Reconstructive Surgery) materials corresponded to “difficult,” with reading categories ranging between high school and university grade levels. Conversely, the LLM‐revised handouts had an average seventh‐grade reading level. LLM‐revised handouts had better readability in nearly all metrics tested: Flesch‐Kincaid Reading Ease (70.8 vs 43.9; P < .05), Gunning Fog Score (10.2 vs 14.42; P < .05), Simple Measure of Gobbledygook (9.9 vs 13.1; P < .05), Coleman‐Liau (8.8 vs 12.6; P < .05), and Automated Readability Index (8.2 vs 10.7; P = .06). PEMAT scores were significantly higher in the LLM‐revised handouts for understandability (91 vs 74%; P < .05) with similar actionability (42 vs 34%; P = .15) when compared to the standard materials. Conclusion Patient‐facing handouts can be augmented by ChatGPT with simple prompting to tailor information with improved readability. This study demonstrates the utility of LLMs to aid in rewriting patient handouts and may serve as a tool to help optimize education materials. Level of Evidence Level VI.
Patterns and Outcomes of Opioid Use Before and After Hospitalization for Critical Illness: A Population-Based Cohort Study
Henry, Nicole , Warner, Matthew A. , Hanson, Andrew C. , Schulte, Phillip J. , Henry, Nicole R, Warner, Matthew A , Warner, Nafisseh S.

Mayo Clinic

Journal of Intensive Care Medicine | August 6, 2024 | Volume: 40 | Issue: 1 | Pages: 85-93

10.1177/08850666241268473 | PMID 39105427 Get It

Background: Hospitalization represents a major access point for prescription opioids, yet little is known regarding patterns and outcomes of opioid exposures before and after hospitalization for critical illness. Methods: This is an observational, population-based cohort study of adults (≥18 years) hospitalized for critical illness from 2010 to 2019. Multivariable models assess associations between opioid exposures prior to hospitalization, classified according to the Consortium to Study Opioid Risks and Trends, and posthospitalization opioid exposures and clinical outcomes through 1-year posthospitalization. Results: Of 11 496 patients, 6318 (55%) were men with a median age of 66 (51, 79) years and 40% (n = 4623) surgical admissions. Prehospitalization opioid availability included 8449 (73%) none, 2117 (18%) short-term, 471 (4%) episodic, and 459 (4%) long-term. Thirty-nine percent (4144/10 708) of hospital survivors were discharged with opioids, with higher prescribing rates for surgical admissions (55%). Greater preadmission opioid exposures were associated with higher prevalent opioid availability at 1 year (odds ratio [95% confidence interval] 24.1 [18.3-31.8], 9.42 [7.18-12.3], and 2.55 [2.08-3.12] for long-term, episodic, and short-term exposures, respectively, vs none, P < .001). Greater preadmission opioid exposures were associated with longer hospitalizations (1.13 [1.04-1.23], 1.15 [1.06-1.25], and 1.08 [1.04-1.13] multiplicative increase in geometric mean, P < .001), more readmissions (hazard ratio [HR] 2.08 [1.74-2.49], 1.88 [1.56-2.26], and 1.48 [1.33-1.64], P < .001), and higher 1-year mortality (HR 1.59 [1.28-1.98], 1.75 [1.41-2.18], and 1.49 [1.32-1.69], P < .001). Similar associations were observed across surgical and nonsurgical admissions. Conclusions: Prehospitalization opioid exposures in survivors of critical illness are associated with clinical outcomes through 1 year and may serve as important prognostic markers.
Simultaneous onset of chronic nonbacterial osteomyelitis in siblings
Patel, Jenny A. , Thomas, Kristen B. , Ristagno, Elizabeth H. , Basiaga, Matthew L.

Mayo Clinic

Modern Rheumatology Case Reports | August 3, 2024 | Volume: 9 | Issue: 1 | Pages: 20-26

10.1093/mrcr/rxae035 | PMID 39096523 Get It

ABSTRACT Chronic nonbacterial osteomyelitis (CNO) is an uncommon autoinflammatory disorder. Significant effort has recently been spent to better define and treat this disorder including development of consensus treatment protocols, validate disease activity tools, and refining classification criteria. However, the underlying immunopathogenesis of the disease remains elusive. In this report, we describe the simultaneous onset of CNO in siblings. A pathogenic gene mutation was not identified, and these sisters lacked a similar biomarker profile. This report highlights that if a genetic predisposition for CNO exists, it may be related to complex polygenic or multifactorial mechanisms of disease evolution.
Association of county level poverty with mortality from primary liver cancers
Ledenko, Matthew , Patel, Tushar , Patel, Tushar

Mayo Clinic

Cancer Medicine | August 3, 2024 | Volume: 13 | Issue: 15 | Pages: No page available

10.1002/cam4.7463 | PMID 39096101 Get It

AbstractBackgroundThe highly variable occurrence of primary liver cancers across the United States emphasize the relevance of location‐based factors. Social determinants such as income, educational attainment, housing, and other factors may contribute to regional variations in outcomes. To evaluate their impact, this study identified and analyzed clusters of high mortality from primary liver cancers and the association of location‐based determinants with mortality across the contiguous United States.MethodsA geospatial analysis of age‐adjusted incidence and standardized mortality rates from primary liver cancers from 2000 to 2020 was performed. Local indicators of spatial association identified hot‐spots, clusters of counties with significantly higher mortality. Temporal analysis of locations with persistent poverty, defined as high (>20%) poverty for at least 30 years, was performed. Social determinants were analyzed individually or globally using composite measures such as the social vulnerability index or social deprivation index. Disparities in county level social determinants between hot‐spots and non‐hot‐spots were analyzed by univariate and multivariate logistic regression.ResultsThere are distinct clusters of liver cancer incidence and mortality, with hotspots in east Texas and Louisiana. The percentage of people living below the poverty line or Hispanics had a significantly higher odds ratio for being in the top quintile for mortality rates in comparison to other quintiles and were highly connected with mortality rates. Current and persistent poverty were both associated with an evolution from non‐hotspots to new hotspots of mortality. Hotspots were predominantly associated with locations with significant levels of socioeconomic vulnerability or deprivation.ConclusionsPoverty at a county level is associated with mortality from primary liver cancer and clusters of higher mortality. These findings emphasize the importance of addressing poverty and related socio‐economic determinants as modifiable factors in public health policies and interventions aimed at reducing mortality from primary liver cancers.
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Jain, Michael D. , Spiegel, Jay Y. , Nastoupil, Loretta J. , Tamaresis, John , Ghobadi, Armin , Lin, Yi , Lekakis, Lazaros J. , Oluwole, Olalekan O. , McGuirk, Joseph P. , Deol, Abhinav , Dorritie, Kathleen , Sehgal, Alison R. , Hill, Brian T. , Ulrickson, Matthew L. , Patel, Dilan A. , Jacobs, Miriam T. , Bansal, Radhika , Patel, Vivek , Rapoport, Aaron P. , Neelapu, Sattva S. , Lunning, Matthew A. , Dahiya, Saurabh , Oluwole, Olalekan O , McGuirk, Joseph , Deol, Abhinav , Goy, Andre Henri , Munoz, Javier L , Ulrickson, Matthew , Westin, Jason R , Chavez, Julio C , Patel, Dilan , Jacobs, Miriam T , Bansal, Radhika , Bennani, N Nora , Rapoport, Aaron P , Vose, Julie , Miklos, David B , Neelapu, Sattva S , Locke, Frederick L , Dahiya, Saurabh , Jain, Michael D , Lin, Yi , Nastoupil, Loretta J , Ghobadi, Armin , Reagan, Patrick Michael , Andreadis, Charalambos Babis , Muñoz, Javier , Westin, Jason R. , Bennani, N. Nora , Vose, Julie M. , Miklos, David B. , Locke, Frederick L.

Mayo Clinic

Journal of Clinical Oncology | August 2, 2024 | Volume: 42 | Issue: 30 | Pages: 3581-3592

10.1200/jco.23.02786 | PMID 39094076 Get It

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of relapse ( P = .02), but a higher risk of NRM compared with patients younger than 60 years (NRM odds ratio, 4.5 [95% CI, 2.1 to 10.8]; P < .001). Late NRM was mainly due to infections and subsequent malignant neoplasms (SMNs). In total, SMNs occurred in 24 patients (9%), including therapy-related myeloid neoplasms (n = 15), solid tumors (n = 7), and unrelated lymphoid malignancies (n = 2). CONCLUSION In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim , Roloff, Gregory W. , Kopmar, Noam E. , Lin, Chenyu , Advani, Anjali S. , Dekker, Simone E. , O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Katharine, Sutherland, Katherine C. , Ahmed, Mohamed , Zambrano, Héctor, Bradshaw, Danielle , Schwartz, Marc S. , Tracy, Sean , Kubiak, Michal Jakub , Mukherjee, Akash , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Ladha, Abdullah , Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , O’Dwyer, Kristen M. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian , Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Bishop, Michael R. , Pullarkat, Vinod , Muffly, Lori , Lin, Chenyu , Advani, Anjali S , Jeyakumar, Nikeshan , Dykes, Kaitlyn C , Chen, Evan , Bradshaw, Danielle , Dholaria, Bhagirathbhai R , Majhail, Navneet S , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Moore, Jozal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Lee, Catherine J , Leonard, Jessica T , Frey, Noelle V , Luskin, Marlise R , Muffly, Lori , Bachanova, Veronika , Aldoss, Ibrahim , Muhsen, Ibrahim N , Sutherland, Katherine , Roloff, Gregory W , Faramand, Rawan , Gupta, Vishal , Dykes, Kaitlyn C. , Mercadal, Santiago , Schwartz, Marc, Dholaria, Bhagirathbhai , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Hilal, Talal , O'Dwyer, Kristin , Tsai, Stephanie B., Kota, Vamsi , Oliai, Caspian H , Frey, Noelle V. , Bishop, Michael Russell , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal

Mayo Clinic

Blood Advances | August 2, 2024 | Volume: 8 | Issue: 23 | Pages: 6139-6147

10.1182/bloodadvances.2024013747 | PMID 39093952 Get It

Abstract The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-naïve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-naïve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P &lt; .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria
Breeggemann, Matthew C. , Wood, Kyle D. , Harris, Peter C. , Lieske, John C. , Tasian, Gregory E.

Mayo Clinic

Journal of Urology | August 2, 2024 | Volume: 212 | Issue: 5 | Pages: 649-659

10.1097/ju.0000000000004147 | PMID 39093847 Get It

Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
Barbier, Emilie, Burmeister, Bryan , Cunningham, David , Grilli, Maurizio , Hofheinz, Ralf‐Dieter , Kieser, Meinhard , Langley, Ruth E. , Lordick, Florian , Mauer, Murielle , Michalski, Christoph , Nankivell, Matthew , Stahl, Michael , Urba, Susan G., Lanschot, Jan van, Vordermark, Dirk , Walsh, T. N. , Proctor, Tanja, Vey, Johannes A. , Cunningham, David , Ronellenfitsch, Ulrich , Friedrichs, Juliane , Bass, Gary Alan , Eyck, Ben M. , Kleeff, Jorg H. , Klevebro, Fredrik , Lutz, Manfred Paul , Michl, Patrick , Nilsson, Magnus , Seide, Svenja , Shah, Manish A , Shi, Qian , Ychou, Marc

Mayo Clinic

JAMA Network Open | August 2, 2024 | Volume: 7 | Issue: 8 | Pages: e2425581

10.1001/jamanetworkopen.2024.25581 | PMID 39093560 Get It

ImportanceThe prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone.ObjectiveTo assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes.Data SourcesLiterature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023.Study SelectionTwo blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria.Data Extraction and SynthesisThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach.Main Outcomes and MeasuresOverall and disease-free survival, postoperative morbidity, and mortality.ResultsThe analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperative and/or perioperative chemotherapy plus surgery (HR, 0.78 [95% CrI, 0.64-0.91]; 3-year difference, 90 deaths per 1000 patients) showed longer overall survival than surgery alone. Comparing the 2 modalities yielded similar overall survival (HR, 1.04 [95% CrI], 0.83-1.28]; 3-year difference, 15 deaths per 1000 patients fewer for CRT). Similarly, disease-free survival was longer for both modalities compared with surgery alone. Postoperative morbidity was more frequent after CRT plus surgery (odds ratio [OR], 2.94 [95% CrI, 1.01-8.59]) than surgery alone. Postoperative mortality was not significantly more frequent after CRT plus surgery than surgery alone (OR, 2.50 [95% CrI, 0.66-10.56]) or after chemotherapy plus surgery than CRT plus surgery (OR, 0.44 [95% CrI, 0.08-2.00]).Conclusions and RelevanceIn this meta-analysis of patients with AEG, both preoperative CRT and preoperative and/or perioperative chemotherapy were associated with longer survival without relevant differences between the 2 modalities. Thus, either of the 2 treatments may be recommended to patients.
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey
Banez, Marisela Tan , Atienza, Sol , Butts, Allison R, Derba, Megan, Dicke, Katie, Haverstick, Kimberly, Heron, Bernadette B. , Cimino, Sarah K, Loop, Matthew Shane , Hough, Shannon , Merten, Julianna A., Taucher, Kate D, Zhang, J, Butts, Allison , Shah, Vishal , Mahmoudjafari, Zahra , Moore, Donald C. , Shah, Vishal

Mayo Clinic

Journal of Oncology Pharmacy Practice | August 2, 2024 | Volume: 31 | Issue: 4 | Pages: 517-527

10.1177/10781552241265280 | PMID 39091073 Get It

Introduction The treatment of cancer is associated with high risk for toxicity and high cost. Strategies to enhance the value, quality, and safety of cancer care are often managed independently of one another. Oncology stewardship is a potential framework to unify these efforts and enhance outcomes. This landscape survey establishes baseline information on oncology stewardship in the United States. Methods The Hematology/Oncology Pharmacy Association (HOPA) distributed a 38-item survey composed of demographic, institutional, clinical decision-making, support staff, metrics, and technology sections to 675 HOPA members between 9 September 2022 and 9 October 2022. Results Most organizations (78%) have adopted general pharmacy stewardship practices; however, only 31% reported having established a formalized oncology stewardship team. More than 70% of respondents reported implementation of biosimilars, formulary management, and dose rounding as oncology stewardship initiatives in both inpatient and outpatient settings. Frequently cited barriers to oncology stewardship included lack of clinical pharmacist availability (74%), lack of oncology stewardship training (62%), lack of physician/provider buy-in (32%), and lack of cost-saving metrics (33%). Only 6.6% of survey respondents reported their organization had defined “value in oncology.” Lack of a formalized stewardship program was most often cited (77%) as the rationale for not defining value. Conclusions Less than one-third of respondents have established oncology stewardship programs; however, most are providing oncology stewardship practices. This manuscript serves as a call to action for stakeholders to work together to formalize oncology stewardship programs that optimize value, quality, and safety for patients with cancer.